Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuprazan for Patients With Dual Antiplatelet Therapy Trial
NCT07479056Recruiting
- Sponsor
- Suk Min Seo
- Start
- Oct 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of fexuprazan in gastrointestinal bleeding (2 arms), sponsored by Suk Min Seo. Primary endpoint: Composite endpoint of upper gastrointestinal clinical events at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
fexuprazan
03
Conditions
gastrointestinal bleeding
Beyond the preview
Go deeper on NCT07479056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479056.